Celcuity
D

CELC

65.300
USD
-0.32
(-0.48%)
Post Trading·64.340USD-0.960(-1.47%)
حجم التداول
0
الربح لكل سهم
-5
العائد الربحي
-
P/E
-15
حجم السوق
3,195,253,592
نظرة عامة
أصول ذات صلة
AMD
AMD
D
Advanced Micro Devices
516.87
9.13(1.80%)
516.40-0.47(-0.09%)
CAN
D
Canaan
0.21800
0.00000(0.00%)
COIN
COIN
D
Coinbase Global
164.440
-4.690(-2.77%)
164.150-0.290(-0.18%)
IBM
IBM
D
International Business Machines Corp
253.540
1.430(0.57%)
253.040-0.500(-0.20%)
INTC
INTC
D
Intel Corp
86.970
1.480(1.73%)
86.570-0.400(-0.46%)
MARA
D
Marathon Digital Holdings
7.02000
-0.23500(-3.24%)
7.01000-0.01000(-0.14%)
MSTR
MSTR
D
MicroStrategy
146.050
0.200(0.14%)
146.460+0.410(+0.28%)
NVDA
NVDA
D
إنفيديا
210.990
-1.300(-0.61%)
211.140+0.150(+0.07%)
RIOT
D
Riot Platforms
12.520
-0.375(-2.91%)
12.500-0.020(-0.16%)
SI
D
Shoulder Innovations Inc
19.690
-0.075(-0.38%)
TSLA
TSLA
D
تيسلا
372.22
-2.45(-0.65%)
371.68-0.54(-0.15%)
المزيد

العنوان: Celcuity

القطاع: الرعاية الصحية
الصناعة: Biotechnology
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer andmetastatic castration-resistant prostate cancer, are ongoing.